Key questions to be discussed at iwCLL 2017: cancer genetics, immunology and categorizing patients
Are combination therapies more effective for the treatment of relapsed refractory CLL?
Can the dream of affordable cancer care come true?
CLL update from ICML17: Current treatment and future directions for patients
iwCLL 2017 program: the biology of CLL, treatment options and the relapsed/refractory setting